(Q37407985)

20 August 2017

1 reference

title

BRCA1/2 mutations and triple negative breast cancers (English)

1 reference

20 August 2017

3

Claudine Isaacs

1 reference

20 August 2017

Beth N Peshkin

1

1 reference

PMC publication ID

3870050

20 August 2017

Michelle L Alabek

series ordinal

2

1 reference

20 August 2017

1 January 2010

1 reference

20 August 2017

1 reference

20 August 2017

32

1 reference

20 August 2017

1-2

1 reference

20 August 2017

25-33

1 reference

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Incorporating tumour pathology information into breast cancer risk prediction algorithms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Triple-negative breast cancer--current status and future directions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Triple negative breast cancers: clinical and prognostic implications.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Validity of models for predicting BRCA1 and BRCA2 mutations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Limited family structure and BRCA gene mutation status in single cases of breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Meta-analysis of BRCA1 and BRCA2 penetrance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Histopathology of BRCA1- and BRCA2-associated breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870050

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer

3 December 2018

1 reference

12 December 2020

The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy

1 reference

12 December 2020

The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified

1 reference

12 December 2020

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

12 December 2020

ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome

1 reference

12 December 2020

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

12 December 2020

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

1 reference

12 December 2020

Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France

1 reference

12 December 2020

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

1 reference

12 December 2020

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients

1 reference

12 December 2020

Identifiers

DOI

10.3233/BD-2010-0306

1 reference

20 August 2017

1 reference

PMC publication ID

3870050

20 August 2017

PubMed publication ID

21778580

1 reference

PMC publication ID

3870050